 |
|
Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial—Correction
Arch Neurol. 2003;60:1728.
Mini-Mental State Examination Scores Erroneously Added. In the Original Contribution by Farlow et al titled "Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial," published in the June issue of the ARCHIVES (2003;60:843-848), 4 Mini-Mental State Examination scores were erroneously added to the text. On page 843, in the "Abstract,""Results" subheading, right-hand column, lines 5 through 9, the sentence should have read: "In these RDO analyses, a statistically significantly greater worsening on the ADAS-Cog mean change score was observed in the placebo group (n = 17) compared with the rivastigmine 6- to 12-mg/d group (n = 33) at week 26."Farther down on the same page, same subsection, lines 13 through 18 should have read: "The RDO analysis also showed a statistically significantly greater decline in cognitive function as measured by the ADAS-Cog mean change score in the placebo group (n = 38) compared with the rivastigmine 6- to 12-mg/d group (n = 88) at week 26." On page 845, "Results" section, "ADAS-Cog Mean Change From Baseline Score" subsection, the first sentence should have read: "The results from the US Pivotal (dose-range) Trial showed a statistically significantly greater worsening on the ADAS-Cog mean change score in the placebo group (n = 17) compared with the rivastigmine 6- to 12-mg/d group (n = 33) at week 26 (Table 2)." Farther down on the page, same subsection lines 9 through 14 should have read: "In the pooled data studies, the RDO analysis also showed a statistically significantly greater decline in cognitive function as measured by the ADAS-Cog mean change score in the placebo group (n = 38) compared with the rivastigmine 6- to 12-mg/d group (n = 88) at 26 weeks."
|
